Who We Are
LYSINE BIOTECH is registered in Tamil Nadu state under ROC-CHENNAI, healthcare and industrial Innovations Made in Tamilnadu, for India and world start-up biotech company established in the year 2018..
We are currently involved new drug development pipeline, from early discovery through Pre-Clinical and Clinical Trials. In addition to Infectious disease drug/vaccine discovery and development, we have also made contributions to projects in biosimilars (mAbs), Diabetes, Oncology, Cardiovascular, and Neuroscience Diseases. We aim to provide affordable, safe, and effective drugs, enzymes, and vaccines for diseases with global prevalence.
Lysine Biotech is committed to product development and manufacturing of drugs, biomarkers, Vaccines, and Enzymes for several diseases and Infectious diseases. Biological molecules are produced from living organisms and range from DNA, mRNA, and protein through in-silico and wet lab technologies, which are useful for medicinal and industrial applications.
Our vision is to make a new approach to provide affordable, safe, and effective biosimilar is a copy of a biological medical drug that is similar, but not identical, to the original biological medical drug, The path to their approval is shorter as clinical trials and spend on research & development is much less than on the original biologic medical drug, thus fostering cheaper cost.
Our vision is to make new approaches in bio better Kilirag-1 drug for treating type 2 diabetes in the obese market is a USD 19.2bn market, which is derived from Glucagon-like peptide 1 (GLP-1), which is a synthetic chemical that can be made from a natural product (i.e. naturally derived) on the Humans (Homo sapiens) proteins. People worldwide are becoming more Synthetic chemical drugs and shifting to Human (Homo sapiens) Proteins-based products. This shift would help increase the demand for the company’s Synthetic chemical drug alternatives. LBPL plans to achieve at least 5% global market share in the next 3-5 years.
Our technology platform can be extensively utilized for low-cost and lower doses/frequency of injections of synthetic chemical drugs.
Our Kilirag-1 platform offers higher active (up to 200 mg), greater bioavailability, improved mechanism of action (MOA), low cost, and lower doses/frequency of injections for a once-8 day, thereby overcoming several formulations and process limitations of current marketed Dosage for Injection, a solution to Route subcutaneous.
The new approaches in the Pan Corona Vaccine market is a USD 350bn to USD 410bn in value annually market, which is derived from proteins, which is a synthetic chemicals that can be made from a natural product (i.e. naturally derived) on the Virus (PAN coronavirus) proteins. People worldwide are becoming more Synthetic chemical protein subunit vaccines and shifting to a virus (PAN coronavirus) protein-based products. This shift would help increase the demand for the company’s Synthetic chemical-based protein subunit vaccine alternatives. LBPL plans to achieve at least 5% global market share in the next 3-5 years.Learn More About Products R&D Pipline
Lysine Biotech's focus areas are several applications in health care and industrial importance
Study of protein stability and evolutionary understanding of proteins, Identification and modification of functional sites, To understanding protein in healthy & disease state
Cerebrospinal fluid (CSF) molecular biomarkers to identify pathological processes in Alzheimer's disease (AD) by using Spondin-1 Proteins, Prevention the buildup of beta-amyloid and stop Alzheimer's disease by inhibiting beta-secretase cleavage of the amyloid precursor protein (APP) by using Spondin-1 Protein
MetabolomicInformatics: Metabolomic Natural products of microorganisms, plants, and animals (Antibiotics, Antivirals, Antifungals, Antimicrobial Resistances, Antibodies) and Industrial (Chemicals and Enzymes) importance, Secondary metabolites produced by solid-state fermentation system and microbial strain identification and improvement
VaccineInformatics: Bioinformatics approaches are used to systematically analyze all available pathogen sequences in public databases(NCBI, EMBL, DDBJ)to identify and characterize candidate vaccine targets for experimental validation.
NeoAg-specific T cells therapy for cancer treatment
Therapeutic strategies involve the reactivation of wild-type TP53 functions by protein modification of DNA binding sites position of amino acids 248 & 249 to isolate clinically relevant neoantigen-reactive (NeoAR T cells) therapy for different types cancer treatment.
1.Long non coding reading frames endless RNA (lncrfeRNA)
Role of thymine in protein coding frames of mRNA sequences” published in the journal" Bioinformation. 2008. 2, 304-307. doi: 10.6026/97320630002304— a new class of programmable medicines capable of expressing therapeutic proteins,chimeric antigen receptors (CARs), Membrane Proteins, Peptides, Antibodies, Vaccine inside the body.
2.Insoluble drug delivery technologies will help in better therapeutic applications. ” Role of large hydrophobic residues in proteins. published in the journal"Bioinformation. 2009. 3, 409-412. doi: 10.6026/97320630003409
3.Development of automated large-scale manufacturing systems for 3rd generation of CAR-T cells
To make a new approach to provide affordable, safe, and effective scFv sequences used for CAR scFv are originated from Pangene Biotech Ltd
Collaborating research between Department of Biomedical Science, Graduate School of Biomedical Science & Engineering, Hanyang University and Lysine Biotech Pvt. Ltd. is ongoingLearn More About Research and Development